Vestal Point Capital LP Sells 240,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Vestal Point Capital LP decreased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 33.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 485,000 shares of the company’s stock after selling 240,000 shares during the quarter. Janux Therapeutics comprises 1.7% of Vestal Point Capital LP’s investment portfolio, making the stock its 20th biggest position. Vestal Point Capital LP’s holdings in Janux Therapeutics were worth $22,034,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after acquiring an additional 378,477 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Janux Therapeutics during the first quarter worth $739,000. Virtu Financial LLC acquired a new position in shares of Janux Therapeutics in the first quarter valued at about $609,000. DNB Asset Management AS bought a new stake in Janux Therapeutics in the 2nd quarter valued at about $221,000. Finally, SG Americas Securities LLC bought a new position in shares of Janux Therapeutics during the second quarter worth approximately $1,452,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insiders Place Their Bets

In other news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the sale, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. This represents a 12.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $45.96, for a total value of $2,298,000.00. Following the sale, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 445,610 shares of company stock worth $20,578,666. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics Trading Down 3.4 %

NASDAQ JANX opened at $46.39 on Friday. The company’s 50 day simple moving average is $49.98 and its two-hundred day simple moving average is $45.83. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Scotiabank cut their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday, November 7th. Leerink Partners assumed coverage on shares of Janux Therapeutics in a research report on Friday, November 22nd. They set an “outperform” rating and a $79.00 price objective for the company. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $67.70.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.